Member Info for gtc1507

Comments on the low share price:

CEO believes value of the business should be Significantly higher than it is now.

“As I presented today we have some really Excellent technologies that can make a very significant impact, complemented by service business that can apply those technologies to real projects with active clients who are trying to get antibodies to market and the clinic, across a wide range of applications, such as therapeutics vet med and diagnostics, across a much wider range of markets than companies our size could possibly hope to assess through other models.

That’s what we’re working towards and speaking for myself and why I came to fusion it’s to make a real step change and get the impact from those new technologies and realise the potential of those in genuine progress both in terms of treating people, identifying and treating diseases but also in terms of fiscal remuneration for the business and really making fusion a huge success.

We have that potential we are now working to realise that potential.

That should impact in a very much significantly improved long term value of the business and we should be seeing that coming through as some of the negative impacts that have weighed heavily on the share price are removed”

CEO’s closing remarks on the investor meet company make clear the downturn is over:

I feel like We’ve been Put through the mill through the last year but we have survived and emerged fitter, stronger and better and we are On the up.

The Future is extremely bright,in fact we’re converting future into the present, things are looking much much better.

I am very very confident about the year ahead, we’re not taking anything for granted in the least but the prospects are looking extremely good so thanks very much for your support and all the time and investment that’s been made, we are converting that into realised potential.

Encouraging also that the S&P XBI biotech index is up 16% from 6 months ago supporting that would appear to be recovering

Not all folks are active/ update their LinkedIn remember and could quite easily retain titles from before the restructure

Yep this one https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2024/05/20240520-Fusion-Antibodies-plc-FAB.L-Allenby-Capital-Update.pdf?c4161=on

Interesting latest broker note indicates Marex Financial now owns 3.1% yet no TR-1 😵‍💫

And also that the share price is cheap and represents an opportunity!

Https://www.proactiveinvestors.co.uk/companies/news/1049097/fusion-antibodies-ceo-highlights-strategic-growth-and-innovations-one2one-investor-forum-1049097.html

Https://youtu.be/39NYX6tWW0M?feature=shared

Took about a week for it to be online last time.

Sea of blue buys today 🥳

Ask moving up - interesting to see if we get more joining the party after tonight’s presentation.

Reminder that CEO at the last investor meeting said Fusion was still involved in this, that it was still progressing well and that they would be popping champagne corks if it comes off.

https://www.qub.ac.uk/Business/futuremedicines/

https://www.qub.ac.uk/Business/futuremedicines/Filetoupload,1026773,en.pdf

Looks to be a consortium of 9 partners with the two Ni universities seeking of £54.4m funding to take forward projects to improve commercialisation, R&D, more efficient drug development and delivery and boost workforce skills in the region.

Hopefully with the NI executive back there will be opportunity for this to progress

Adrian mentioned more videos were online about Optimal. Found this presentation on their site.

https://youtu.be/q93lAdxRE2Y?feature=shared

4 proof of concept studies - one targeting an area forecast to be worth 77bn in 2026 (16 minutes 54 in)

Https://www.linkedin.com/posts/invest-northern-ireland-americas_bio-bio2024-biosandiego-activity-7201297387770789889-RHhi?utm_source=share&utm_medium=member_ios

Anyone planning the investor presentation in person? Took about a week before the last was available online so would be goood to get an early readout

Buys also being shown as sells as 3.79

Bit of a shake

Hopefully we can continue the strong momentum of last week upwards.

With good news think this should be higher

Still think this is an extremely bullish para by the analysts. Rare they nail their flag so clearly to the masts….

Fusion's market capitalisation is £3.3m, suggesting an EV of £2.1m, based on year £1.2m end cash. We consider this to represent an interesting special situation geared to the success of Fusion's recovery plan, where almost no value is currently being ascribed to its class leading antibody discovery technologies. This unusual situation has arisen as a result of the steep decline in revenue Fusion experienced in H2 FY23 that extended into FY24.

Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion's class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an Al-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m.